MARKET

SAGE

SAGE

Sage Therapeutic
NASDAQ
7.26
+0.02
+0.28%
After Hours: 7.16 -0.1 -1.38% 17:33 02/05 EST
OPEN
7.28
PREV CLOSE
7.24
HIGH
7.30
LOW
7.16
VOLUME
1.89M
TURNOVER
--
52 WEEK HIGH
27.39
52 WEEK LOW
4.620
MARKET CAP
444.12M
P/E (TTM)
-1.3013
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at SAGE last week (0127-0131)?
Weekly Report · 3d ago
Notable Healthcare headlines for the week: Moderna, AbbVie, Thermo Fisher, J&J in focus
Seeking Alpha · 4d ago
Deal Dispatch: Sage And Silvus Are Up For Sale, MrBeast Secures $20B For TikTok
Benzinga · 5d ago
The Zacks Analyst Blog Highlights Sage Therapeutics, Biogen, Cytokinetics and Akero Therapeutics
NASDAQ · 01/30 14:55
SAGE THERAPEUTICS INC <SAGE.O>: MIZUHO RAISES TARGET PRICE TO $9 FROM $6
Reuters · 01/30 11:46
Sage Therapeutics price target raised to $9 from $6 at Mizuho
TipRanks · 01/29 21:55
SAGE Therapeutics (SAGE) Gets a Hold from Mizuho Securities
TipRanks · 01/29 21:55
SAGE Rejects Biogen's Offer to Buy Remaining Stake, Stock Up
NASDAQ · 01/28 16:54
More
About SAGE
Sage Therapeutics, Inc. is a biopharmaceutical company. The Company has developed the two FDA-approved treatments indicated for postpartum depression and is advancing a robust pipeline to target unmet needs in brain health. The Company is targeting diseases and disorders of the brain across its clinical development and earlier stage pipeline. Its product ZURZUVAE is for the treatment of postpartum depression (PPD) in adults. ZURZUVAE is a neuroactive steroid that is a positive allosteric modulator of GABA receptors, targeting both synaptic and extra synaptic GABA receptors. Its product ZULRESSO (brexanolone) CIV injection is for the treatment of PPD in individuals 15 years old and older. It is also developing a portfolio of other novel compounds that target GABA receptors, including SAGE-324, which is a novel GABAA receptor positive allosteric modulator intended for chronic oral dosing. Its second area of focus for development is novel compounds that target the NMDA receptor.

Webull offers SAGE Therapeutics Inc stock information, including NASDAQ: SAGE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SAGE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SAGE stock methods without spending real money on the virtual paper trading platform.